Search clinical trials for: CDB 2914

Total 1970 results

Eunice Kennedy Shriver National Institute of Child...

Completed

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

Healthy

United States
Assiut University

Not yet recruiting

Immune Markers in Pediatric ITP on Second Line Therapy

ITP - Immune Thrombocytopenia
Eunice Kennedy Shriver National Institute of Child...

Completed

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

Leiomyoma

United States
Eunice Kennedy Shriver National Institute of Child...

Withdrawn

CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women

Urogenital Abnormalities
Population Council

Completed

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

Contraception

United States, Dominican Republic, Chile
HRA Pharma

Completed

Safety and Efficacy of CDB-2914 for Emergency Contraception

Emergency Contraception

United States
Eunice Kennedy Shriver National Institute of Child...

Completed

Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause

Postmenopause

United States
HRA Pharma

Completed

Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

Contraception

Chile, Dominican Republic
HRA Pharma

Completed

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Contraception

United States, Ireland, United Kingdom
University of Pittsburgh
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Efficacy Trial of CDB 2914 for Emergency Contraception

Emergency Contraception

United States
University Health Network, Toronto

Recruiting

Improving Pain Disability With the Use of Oral Cannabinoids

Chronic Pain | Cannabis | Opioid Use

Canada
Assistance Publique - Hôpitaux de Paris

Completed

Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus (CTLantiCMV)

Cytomegalovirus Infections | Adenovirus Infections

France
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (P1A114919)

Multiple Sclerosis, Relapsing-Remitting

Australia
Eunice Kennedy Shriver National Institute of Child...
HRA Pharma

Completed

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

Leiomyoma

United States
Kazakhstan's Medical University "KSPH"
Vyacheslav Notanovich Lokshin; Nurgalieva Zhanar Zhenisovna; Manzhuova Lyazzat... and other collaborators

Completed

Health Status of Children Born After Assisted Reproductive Technologies

Child Development | Health Status | Children Born After Assisted Reproductive Technologies

Kazakhstan
Centre Hospitalier Universitaire de Nice

Recruiting

Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy With Second-generation Anti-integrase Drugs on Triple Versus Dual Therapy (COLLATERAL 2)

Hiv

France
Repros Therapeutics Inc.

Terminated

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Nantes University Hospital

Completed

Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis (Prévall-DP)

Allergic Rhinitis | Atopic Dermatitis | Allergic Asthma

France
Takeda
Intra-Cellular Therapies, Inc.

Terminated

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

Schizophrenia

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Alzheimer Disease

United States
Ono Pharmaceutical Co. Ltd

Completed

Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects

Healthy Volunteers

Japan
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
Sohag University

Not yet recruiting

The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia

Immune Thrombocytopenia

Egypt
All India Institute of Medical Sciences, New Delhi

Completed

A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation

Oral Mucositis

India
Nektar Therapeutics

Completed

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors (NKTR-214)

Unspecified Adult Solid Tumor, Protocol Specific

United States
FA Corporation
University of Texas Southwestern Medical Center

Enrolling by invitation

Histological Study of the Effects of a 2910 nm Fiber Laser Technology

Skin Laxity

United States
NervGen Pharma

Recruiting

NVG-291 in Spinal Cord Injury Subjects

Spinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord Injury

United States
Repros Therapeutics Inc.

Terminated

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Endometriosis

United States
Mitsubishi Tanabe Pharma Corporation

Completed

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Q32 Bio Inc.
Innovaderm Research Inc.

Recruiting

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Alopecia Areata

United States
AdAlta Limited

Completed

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

Chronic Kidney Diseases | Interstitial Lung Disease

Australia
AdAlta Limited

Completed

Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers

Interstitial Lung Disease

Australia
Intra-Cellular Therapies, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

Heart Failure, Systolic

United States
Intra-Cellular Therapies, Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

Parkinson Disease

United States
Q32 Bio Inc.

Recruiting

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Atopic Dermatitis

United States
NervGen Pharma

Completed

A Phase I Safety Study of NVG-291 in Healthy Adults

Spinal Cord Injury

Australia
Q32 Bio Inc.

Completed

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

Safety Issues

Australia
Intra-Cellular Therapies, Inc.
Laureate Institute for Brain Research, Inc.

Completed

Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement

Healthy Volunteers

United States
Repros Therapeutics Inc.

Completed

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Uterine Fibroids

United States
Fayoum University

Completed

GCF miRNA-223 , -214 Levels in Smokers and Nonsmokers Periodontitis Patients

Periodontitis, Adult

Egypt
Orsenix LLC

Completed

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Advanced Hematological Disorders

United States
The Dial Corporation
TKL Research, Inc.; Hill Top Research

Completed

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

Common Cold

United States
Hartford Hospital
Yale University

Active, not recruiting

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

CBD

United States
Calithera Biosciences, Inc
Nektar Therapeutics

Withdrawn

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, Canada
Johns Hopkins University
Cultivate Biologics

Completed

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Cannabis

United States
Repros Therapeutics Inc.

Completed

Determination of the Lowest, Safe and Effective Dose of Proellex

Amenorrhea

United States
Repros Therapeutics Inc.

Completed

Proellex Pharmacokinetics Bridging Study

Healthy

United States
The Cleveland Clinic

Completed

Clinical Trial to Evaluate the Endoscopic Ultrasound Guided Celiac Plexus Block for Treatment of Pain in Chronic Pancreatitis

Abdominal Pain | Pancreatitis, Chronic

United States
National Cancer Institute (NCI)

Terminated

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditions

United States

3

Subscribe